Company announcement – No. 30/2018
Financial calendar for Zealand Pharma in 2019
Copenhagen, December 10, 2018 – Zealand Pharma A/S (“ZEAL”) announces the following dates for the company's planned financial reporting in 2019:
7 March Full year announcement and Annual Report 2018
16 May Interim report for the first three months of 2019
15 August Interim report for first half 2019
14 November Interim report for the first nine months of 2019
Zealand's Annual General Meeting will be held on April 4, 2019.
For further information, please contact:
Mats Blom, Executive Vice President and Chief Financial Officer
Tel.: +45 31 53 79 73, e-mail: mabl@zealandpharma.com
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of innovative peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s current pipeline of internal product candidates focus on specialty gastrointestinal and metabolic diseases. Zealand’s portfolio also includes two clinical license collaborations with Boehringer Ingelheim.
Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or follow Zealand on LinkedIn or Twitter @ZealandPharma.
Attachment
